Cabergoline
Cabergoline is an ergot derivative and a potent, long-acting dopamine receptor agonist with high affinity for D2 receptors. By stimulating dopamine D2 receptors in the pituitary gland, it directly inhibits the secretion of prolactin, a hormone that stimulates milk production and regulates reproductive functions.
Dosage by Body Weight
The standard starting dose for hyperprolactinemia is 0.25 mg twice weekly. The dosage may be increased by 0.25 mg twice weekly up to a maximum of 1 mg twice weekly, depending on the patient's serum prolactin levels. Dose increases should not occur more rapidly than every 4 weeks. It is best taken with food to reduce potential side effects like nausea.
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Cabergoline is not indicated or recommended for pediatric use in this weight range. Safety and efficacy have not been established.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Cabergoline is not indicated or recommended for pediatric use in this weight range. Safety and efficacy have not been established.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Cabergoline is not indicated or recommended for pediatric use in this weight range. Safety and efficacy have not been established.
- Body Weight
- 11-15 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Cabergoline is not indicated or recommended for pediatric use in this weight range. Safety and efficacy have not been established.
- Body Weight
- 16-20 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Cabergoline is not indicated or recommended for pediatric use in this weight range. Safety and efficacy have not been established.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | N/A | Cabergoline is not indicated or recommended for pediatric use in this weight range. Safety and efficacy have not been established. |
| 5-7 kg | Not recommended | N/A | Cabergoline is not indicated or recommended for pediatric use in this weight range. Safety and efficacy have not been established. |
| 8-10 kg | Not recommended | N/A | Cabergoline is not indicated or recommended for pediatric use in this weight range. Safety and efficacy have not been established. |
| 11-15 kg | Not recommended | N/A | Cabergoline is not indicated or recommended for pediatric use in this weight range. Safety and efficacy have not been established. |
| 16-20 kg | Not recommended | N/A | Cabergoline is not indicated or recommended for pediatric use in this weight range. Safety and efficacy have not been established. |
Formulation
Purpose
Mainly used to treat hyperprolactinemia (excessive levels of prolactin in the blood), including prolactin-secreting pituitary adenomas (micro- and macroprolactinomas), and idiopathic hyperprolactinemia. It is also used in the management of Parkinson's disease as a second-line therapy and for physiological lactation suppression.
Generic Name
CabergolineBranded Drug Names
Cabergoline is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:
Scheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.